Pirotte B, Ouedraogo R, de Tullio P, Khelili S, Somers F, Boverie S, Dupont L, Fontaine J, Damas J, Lebrun P
Laboratoire de Chimie Pharmaceutique, Université de Liège, 1, Avenue de l'Hôpital, CHU, tour 4, B-4000 Liège, Belgium.
J Med Chem. 2000 Apr 20;43(8):1456-66. doi: 10.1021/jm991069o.
A series of 3-alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1, 1-dioxides structurally related to diazoxide and pinacidil were synthesized and tested as possible K(ATP) channel openers on isolated pancreatic endocrine tissue as well as on isolated vascular, intestinal, and uterine smooth muscle. In contrast to previously described 3-alkylamino-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1, 1-dioxides, most of the new compounds were found to be poorly active on B-cells but exhibited clear vasorelaxant properties. 3-(3, 3-Dimethyl-2-butylamino)-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1, 1-dioxide (4d) and 7-chloro-3-(3, 3-dimethyl-2-butylamino)-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1, 1-dioxide (5d), two compounds bearing the alkyl side chain of pinacidil, were found to be the most active representatives of their respective series on rat aorta rings. 3-Cycloalkylalkylamino- and 3-aralkylamino-7-chloro-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1, 1-dioxides also expressed myorelaxant activity on electrically stimulated guinea pig ileum and on oxytocin-induced contractions of the rat uterus. Further biological investigations ((86)Rb efflux measurements, vasodilator potency on 30 and 80 mM KCl-induced contractions in the absence and presence of glibenclamide) revealed that compounds 4d and 5d, but not compound 5f, expressed the pharmacological profile of classical K(ATP) channel openers. In conclusion, by changing the position of the nitrogen atom in the pyridine ring, we now have obtained a family of drugs expressing an opposite tissue selectivity. Taken as a whole, the present findings also suggest that 3-alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1, 1-dioxides such as 4c, 4d, 5c, and 5d may be considered as new examples of K(ATP) channel openers expressing a pharmacological profile similar to that of pinacidil and diazoxide.
合成了一系列与二氮嗪和吡那地尔结构相关的3-烷基氨基-4H-吡啶并[2,3-e]-1,2,4-噻二嗪1,1-二氧化物,并在分离的胰腺内分泌组织以及分离的血管、肠道和子宫平滑肌上作为可能的K(ATP)通道开放剂进行了测试。与先前描述的3-烷基氨基-4H-吡啶并[4,3-e]-1,2,4-噻二嗪1,1-二氧化物相反,发现大多数新化合物对B细胞活性较差,但具有明显的血管舒张特性。3-(3,3-二甲基-2-丁基氨基)-4H-吡啶并[2,3-e]-1,2,4-噻二嗪1,1-二氧化物(4d)和7-氯-3-(3,3-二甲基-2-丁基氨基)-4H-吡啶并[2,3-e]-1,2,4-噻二嗪1,1-二氧化物(5d)这两种带有吡那地尔烷基侧链的化合物,被发现是它们各自系列中对大鼠主动脉环活性最高的代表。3-环烷基烷基氨基-和3-芳烷基氨基-7-氯-4H-吡啶并[2,3-e]-1,2,4-噻二嗪1,1-二氧化物对电刺激的豚鼠回肠和催产素诱导的大鼠子宫收缩也表现出肌松活性。进一步的生物学研究((86)Rb外流测量、在无和有格列本脲存在下对30和80 mM KCl诱导的收缩的血管舒张效力)表明,化合物4d和5d,但不是化合物5f,表现出经典K(ATP)通道开放剂的药理学特征。总之,通过改变吡啶环中氮原子的位置,我们现在获得了一类表现出相反组织选择性的药物。总体而言,目前的研究结果还表明,3-烷基氨基-4H-吡啶并[2,3-e]-1,2,4-噻二嗪1,1-二氧化物,如4c、4d、5c和5d,可被视为表现出与吡那地尔和二氮嗪相似药理学特征的K(ATP)通道开放剂的新例子。